Karyopharm Therapeutics reported a first-quarter revenue of $30 million, a decline from $33.1 million in the same period last year, primarily due to increased product return provisions for its cancer drug, XPOVIO. U.S. net product revenue for XPOVIO fell to $21.1 million, influenced by a $5 million rise in product return reserves. The company anticipates total revenue for 2025 to be at the lower end of its guidance, between $140 million and $155 million, reflecting the impact of atypical returns.

Despite the revenue dip, Karyopharm’s Phase 3 SENTRY trial for selinexor in myelofibrosis has passed its futility analysis, with enrollment nearing completion. The company maintains a bullish outlook on selinexor’s potential, projecting peak U.S. revenue could reach $1 billion if approved. Additionally, royalty revenue surged 57% year-over-year, driven by global partnerships, indicating strong market demand for its products.

For market professionals, Karyopharm’s focus on extending its cash runway and managing product returns will be crucial as it navigates the upcoming phases of its clinical trials and seeks to capitalize on the anticipated approval of selinexor in myelofibrosis.

Source: fool.com